ARE YOU LIVING WITH ALZHEIMER’S DISEASE?

You may be eligible for an important research study of an investigational medication, azeliragon, that may slow the progression of disease.

Learn more by visiting: livingsteadfast.com

Speak to your doctor to learn more about participating in this study. Payment may be available for time and travel.

Contact:
Shani Bardach
(859) 323-1331
shbardach@uky.edu

Learn more by visiting: livingsteadfast.com
Some Important Facts to Know About Alzheimer’s Disease

- Alzheimer’s disease was initially identified more than 100 years ago. However, research into its symptoms, causes, risk factors, and treatment has gained momentum only in the last 30 years.

- While research has provided a lot of information about the disease, the exact cause of Alzheimer’s is still unknown.

- One in nine people over the age of 65 have Alzheimer’s. For up to 5% of the more than 5 million Americans with Alzheimer’s, the onset of the disease will occur in their 40s or 50s.

- In 2013, unpaid caregivers, typically immediate family members, gave an estimated 17.7 billion hours of their time to care for loved ones with Alzheimer’s.

- Not only are women more likely to have Alzheimer’s, they are also more likely to be caregivers of those with Alzheimer’s.

What is the STEADFAST Study?

The STEADFAST Study is a clinical trial, or research study, that will evaluate a new investigational medication, azeliragon (TTP488), as an addition to many of the commonly prescribed medications for patients with mild-stage Alzheimer’s disease. Azeliragon works by blocking a receptor in the brain that binds to substances such as amyloid beta, a protein thought to contribute to the symptoms of Alzheimer’s disease.

There will be two groups of people in the study:

- One group will receive azeliragon (5 mg daily taken orally) in addition to their regular medication(s).

- One group will receive a placebo (a substance with no active ingredients) in addition to their regular medication(s).

Why should I consider participating in the STEADFAST Study?

- By participating in this study, you can learn more about the treatment of Alzheimer’s disease.

- You may receive the study medication, azeliragon, which may be effective at slowing the progression of Alzheimer’s disease.

- Participating in studies helps advance research, which may help the future treatment of this currently incurable disease.

Do I qualify for this study?

You may qualify for this study if you:

- Have been diagnosed with mild Alzheimer’s disease.

- Are at least 50 years of age.

- Have been taking one or more of the following medications for at least 3 months: memantine (Namenda® or Ebixa®), galantamine (Razadyne® or Reminyl®), Aricept® or Exelon®.

What will I need to do for the STEADFAST Study?

- The study will last approximately 23 months and involves about 9 visits to the doctor’s office, with most visits occurring every 3 months.

- You must attend all study visits with your caregiver.

- You will need to take your study medication every day, as instructed.

- You must continue to take your regular Alzheimer’s disease medication as you normally do.

- You will need to tell the study doctor of any changes to your health or medications while in the study.